3D Bioprinitng technologies for the enhancement and application of functional lung organoid models
Respiratory diseases, ranging from minor infections to serious chronic diseases and malignancies, negatively affect the respiratory system and are influenced by various environmental factors such as air pollution, occupational hazards, and tobacco smoke, as well as lifestyle, genetic causes, and infectious agents. The prevalence and severity of respiratory diseases requires the development of advanced models to better understand their pathophysiology and develop effective treatments. In this context, 3D bioprinting technology is emerging as an innovative tool to create functional lung organoid models. The use of induced pluripotent stem cells (iPSCs) and extracellular matrix (ECM) in bioprinting enables the development of organoids that closely mimic human lung tissue. Bioprinting-based organoids can better replicate the dynamic environment of the human lung, facilitating more accurate disease modeling and drug testing. In this review, we highlight the potential of bioprinted lung organoids in understanding the mechanisms of chronic respiratory diseases, testing the efficacy and safety of new drugs, and exploring regenerative medicine approaches. The integration of advanced bioprinting and organoid technologies is a promising field in respiratory disease research and treatment, offering new hope for patients suffering from lung diseases.
Authors
- Minkyoung Lee (ORCID: https://orcid.org/0000-0002-3956-7288)
- Jimin Jang (ORCID: https://orcid.org/0000-0002-1796-2164)
- Jooyoung Lee (ORCID: https://orcid.org/0000-0003-4752-3792)
- Hyungseok Lee (ORCID: https://orcid.org/0000-0003-0630-5772)
- Se‐Ran Yang (ORCID: https://orcid.org/0000-0002-2422-213X)
- Sangryul Cha
Publication Details
- Journal
- International Journal of Bioprinting
- Published
- 2024-08-16
- DOI
- https://doi.org/10.36922/ijb.4092
- Citations
- 1
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.42